ID

14371

Description

A Dose-Finding Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Adalimumab in Subjects With Refractory Asthma; ODM derived from: https://clinicaltrials.gov/show/NCT00512863

Lien

https://clinicaltrials.gov/show/NCT00512863

Mots-clés

Versions (1)
  1. 12/04/2016 12/04/2016 -
Détendeur de droits

CC BY-NC 3.0

Téléchargé le

12 avril 2016

DOI

Pour une demande vous connecter.

Licence

Creative Commons BY-NC 3.0
Modèle Commentaires :

Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.

Retour au modèle Commentaires
Groupe Item commentaires pour :

Item commentaires pour :

Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.

Eligibility Asthma NCT00512863

Anglais

Eligibility Asthma NCT00512863

1 Formulaires  
  1. StudyEvent: Eligibility
    1. Eligibility Asthma NCT00512863
Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
documented history of refractory asthma, as defined by the american thoracic society,31 defined as 1 major and at least 2 minor criteria
Description

refractory asthma

Type de données

boolean

Alias
UMLS CUI [1,1]
C0004096
UMLS CUI [1,2]
C0205269
actual or documented history of reversible airway obstruction
Description

reversible airway obstruction

Type de données

boolean

Alias
UMLS CUI [1,1]
C0001883
UMLS CUI [1,2]
C0205343
baseline fev1 of 40% − 80% of the predicted for height, age, and sex at screening, as demonstrated 6 or more hours after a short-acting -agonist and/or 24 or more hours after a long-acting -agonist
Description

fev1

Type de données

boolean

Alias
UMLS CUI [1]
C0748133
UMLS CUI [2]
C1373132
history of at least 1 asthma exacerbation leading to oral, iv or im corticosteroid or er/urgent care center visit or hospitalization within the past year prior to screening. this asthma exacerbation should not have been within 30 days prior to screening
Description

asthma exacerbation

Type de données

boolean

Alias
UMLS CUI [1,1]
C0349790
UMLS CUI [1,2]
C0040223
UMLS CUI [2]
C4039704
UMLS CUI [3]
C2065041
UMLS CUI [4]
C0583237
UMLS CUI [5]
C0019993
adequate cardiac, renal and hepatic function as determined by the principal investigator and demonstrated by screening laboratory evaluations, questionnaires, and physical examination results that are within normal limits
Description

renal and hepatic function

Type de données

boolean

Alias
UMLS CUI [1]
C0232804
UMLS CUI [2]
C0232741
subjects must be able to self-inject study medication or have a designee or healthcare professional who can inject the study medication
Description

subjects must be able to self-inject study medication or have a designee or healthcare professional who can inject the study medication

Type de données

boolean

Alias
UMLS CUI [1,1]
C1533685
UMLS CUI [1,2]
C1321605
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
active lung diseases (e.g., bronchitis, chronic obstructive pulmonary disease [copd], interstitial lung disease, pulmonary fibrosis) other than asthma
Description

lung diseases

Type de données

boolean

Alias
UMLS CUI [1]
C0024115
current treatment for corticosteroid-resistant asthma (e.g., methotrexate [mtx], cyclosporine, gold salts, troleandomycin, immune globulin intravenous [igiv], mycophenolate mofetil)
Description

corticosteroid resistant asthma

Type de données

boolean

Alias
UMLS CUI [1,1]
C0004096
UMLS CUI [1,2]
C0001617
UMLS CUI [1,3]
C0332325
UMLS CUI [2]
C0087111
history of cancer or lymphoproliferative disease other than a successfully and completely treated cutaneous squamous cell or basal cell carcinoma or carcinoma −
Description

cancer history

Type de données

boolean

Alias
UMLS CUI [1]
C1512706
UMLS CUI [2]
C0007117
in-situ of the cervix.
Description

cervix carcinoma

Type de données

boolean

Alias
UMLS CUI [1,1]
C0302592
UMLS CUI [1,2]
C0851135
history of listeria, human immunodeficiency virus (hiv), chronic or active hepatitis b, an immunodeficiency syndrome, central nervous system (cns) demyelinating disease or active tb
Description

listeria, hiv, hepatitis b, immunodeficiency syndrome, cns demyelinating disease or active tb

Type de données

boolean

Alias
UMLS CUI [1]
C0023859
UMLS CUI [2]
C0019682
UMLS CUI [3]
C0019163
UMLS CUI [4]
C0019163
UMLS CUI [5]
C0011303
UMLS CUI [6]
C0041296
females who are pregnant or will not discontinue breast-feeding.
Description

pregnancy or lactation

Type de données

boolean

Alias
UMLS CUI [1]
C0032961
UMLS CUI [2]
C0006147
subject with a history of clinically significant drug or alcohol abuse in the last year
Description

drug or alcohol abuse

Type de données

boolean

Alias
UMLS CUI [1]
C0038586
subjects with a poorly controlled medical condition.
Description

poorly controlled medical condition

Type de données

boolean

Alias
UMLS CUI [1]
C0009488
abnormal, clinically significant screening laboratory and other analyses (including ecg).
Description

abnormal laboratory values

Type de données

boolean

Alias
UMLS CUI [1]
C1254595
UMLS CUI [2]
C0009488
subjects with any prior exposure to tysabri® (natalizumab)
Description

exposure to tysabri

Type de données

boolean

Alias
UMLS CUI [1,1]
C0332157
UMLS CUI [1,2]
C1172734
prior treatment with any tnf antagonist, including adalimumab
Description

prior treatment with any tnf antagonist, including adalimumab

Type de données

boolean

Alias
UMLS CUI [1,1]
C1514463
UMLS CUI [1,2]
C1122087
Retour au début de la page

Similar models

Eligibility Asthma NCT00512863

1 Formulaires
  1. StudyEvent: Eligibility
    1. Eligibility Asthma NCT00512863
Name
Type
Description | Question | Decode (Coded Value)
Type de données
Alias
Item Group
C1512693 (UMLS CUI)
refractory asthma
Item
documented history of refractory asthma, as defined by the american thoracic society,31 defined as 1 major and at least 2 minor criteria
boolean
C0004096 (UMLS CUI [1,1])
C0205269 (UMLS CUI [1,2])
reversible airway obstruction
Item
actual or documented history of reversible airway obstruction
boolean
C0001883 (UMLS CUI [1,1])
C0205343 (UMLS CUI [1,2])
fev1
Item
baseline fev1 of 40% − 80% of the predicted for height, age, and sex at screening, as demonstrated 6 or more hours after a short-acting -agonist and/or 24 or more hours after a long-acting -agonist
boolean
C0748133 (UMLS CUI [1])
C1373132 (UMLS CUI [2])
asthma exacerbation
Item
history of at least 1 asthma exacerbation leading to oral, iv or im corticosteroid or er/urgent care center visit or hospitalization within the past year prior to screening. this asthma exacerbation should not have been within 30 days prior to screening
boolean
C0349790 (UMLS CUI [1,1])
C0040223 (UMLS CUI [1,2])
C4039704 (UMLS CUI [2])
C2065041 (UMLS CUI [3])
C0583237 (UMLS CUI [4])
C0019993 (UMLS CUI [5])
renal and hepatic function
Item
adequate cardiac, renal and hepatic function as determined by the principal investigator and demonstrated by screening laboratory evaluations, questionnaires, and physical examination results that are within normal limits
boolean
C0232804 (UMLS CUI [1])
C0232741 (UMLS CUI [2])
subjects must be able to self-inject study medication or have a designee or healthcare professional who can inject the study medication
Item
subjects must be able to self-inject study medication or have a designee or healthcare professional who can inject the study medication
boolean
C1533685 (UMLS CUI [1,1])
C1321605 (UMLS CUI [1,2])
Item Group
C0680251 (UMLS CUI)
lung diseases
Item
active lung diseases (e.g., bronchitis, chronic obstructive pulmonary disease [copd], interstitial lung disease, pulmonary fibrosis) other than asthma
boolean
C0024115 (UMLS CUI [1])
corticosteroid resistant asthma
Item
current treatment for corticosteroid-resistant asthma (e.g., methotrexate [mtx], cyclosporine, gold salts, troleandomycin, immune globulin intravenous [igiv], mycophenolate mofetil)
boolean
C0004096 (UMLS CUI [1,1])
C0001617 (UMLS CUI [1,2])
C0332325 (UMLS CUI [1,3])
C0087111 (UMLS CUI [2])
cancer history
Item
history of cancer or lymphoproliferative disease other than a successfully and completely treated cutaneous squamous cell or basal cell carcinoma or carcinoma −
boolean
C1512706 (UMLS CUI [1])
C0007117 (UMLS CUI [2])
cervix carcinoma
Item
in-situ of the cervix.
boolean
C0302592 (UMLS CUI [1,1])
C0851135 (UMLS CUI [1,2])
listeria, hiv, hepatitis b, immunodeficiency syndrome, cns demyelinating disease or active tb
Item
history of listeria, human immunodeficiency virus (hiv), chronic or active hepatitis b, an immunodeficiency syndrome, central nervous system (cns) demyelinating disease or active tb
boolean
C0023859 (UMLS CUI [1])
C0019682 (UMLS CUI [2])
C0019163 (UMLS CUI [3])
C0019163 (UMLS CUI [4])
C0011303 (UMLS CUI [5])
C0041296 (UMLS CUI [6])
pregnancy or lactation
Item
females who are pregnant or will not discontinue breast-feeding.
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
drug or alcohol abuse
Item
subject with a history of clinically significant drug or alcohol abuse in the last year
boolean
C0038586 (UMLS CUI [1])
poorly controlled medical condition
Item
subjects with a poorly controlled medical condition.
boolean
C0009488 (UMLS CUI [1])
abnormal laboratory values
Item
abnormal, clinically significant screening laboratory and other analyses (including ecg).
boolean
C1254595 (UMLS CUI [1])
C0009488 (UMLS CUI [2])
exposure to tysabri
Item
subjects with any prior exposure to tysabri® (natalizumab)
boolean
C0332157 (UMLS CUI [1,1])
C1172734 (UMLS CUI [1,2])
prior treatment with any tnf antagonist, including adalimumab
Item
prior treatment with any tnf antagonist, including adalimumab
boolean
C1514463 (UMLS CUI [1,1])
C1122087 (UMLS CUI [1,2])
Retour au début de la page 

Contact

Utilisez ce formulaire pour les retours, les questions et les améliorations suggérées.

Les champs marqués d’un * sont obligatoires.

Aide

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial